Arax Advisory Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $46.3K | Sell |
305
-89
| -23% | -$13.5K | ﹤0.01% | 1277 |
|
|
2025
Q1 | $59.3K | Buy |
394
+4
| +1% | +$602 | ﹤0.01% | 897 |
|
|
2024
Q4 | $72K | Buy |
390
+209
| +115% | +$38.6K | ﹤0.01% | 784 |
|
|
2024
Q3 | $35.7K | Buy |
181
+46
| +34% | +$9.06K | ﹤0.01% | 847 |
|
|
2024
Q2 | $27.9K | Buy |
135
+38
| +39% | +$7.85K | ﹤0.01% | 867 |
|
|
2024
Q1 | $26.3K | Hold |
97
| – | – | ﹤0.01% | 623 |
|
|
2023
Q4 | $22.9K | Hold |
97
| – | – | ﹤0.01% | 625 |
|
|
2023
Q3 | $19K | Hold |
97
| – | – | ﹤0.01% | 593 |
|
|
2023
Q2 | $20.4K | Hold |
97
| – | – | ﹤0.01% | 584 |
|
|
2023
Q1 | $19.6K | Sell |
97
-15
| -13% | -$3.03K | ﹤0.01% | 590 |
|
|
2022
Q4 | $24.4K | Hold |
112
| – | – | ﹤0.01% | 540 |
|
|
2022
Q3 | $22K | Sell |
112
-50
| -31% | -$9.82K | ﹤0.01% | 556 |
|
|
2022
Q2 | $35K | Buy |
+162
| New | +$35K | 0.01% | 474 |
|